Status:
COMPLETED
Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B
Lead Sponsor:
Novartis
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
16-70 years
Phase:
PHASE3
Brief Summary
This study is being conducted to compare the effectiveness and safety of telbivudine (LdT) and lamivudine in Chinese adults.
Eligibility Criteria
Inclusion
- Documented clinical history compatible with chronic hepatitis B infection
- Other protocol-defined inclusion criteria may apply
Exclusion
- Patient is pregnant or breastfeeding
- Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV
- Patient has previously received lamivudine or any investigational anti-HBV nucleoside or nucleotide analog
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00131742
Start Date
July 1 2004
End Date
January 1 2007
Last Update
May 12 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, China